Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
J Shoulder Elb Arthroplast ; 3: 2471549219832442, 2019.
Article in English | MEDLINE | ID: mdl-34497946

ABSTRACT

BACKGROUND: The subscapularis tendon is commonly released during shoulder arthroplasty, and its integrity and repair postoperatively have been shown important to help maximize patient function. However, diagnosing subscapular tendon failure can be difficult with magnetic resonance imaging secondary to metal artifact as well as very costly. PURPOSE: The purpose of this study was to assess the utility of ultrasound imaging in evaluating subscapularis integrity at specific time points following shoulder arthroplasty, in a blinded fashion. Secondarily, we report on the correlation between the condition of the subscapularis and quality-of-life outcome measures. STUDY DESIGN: Prospective case series. METHODS: Ultrasounds were completed preoperatively and postoperatively at 1 week as well as at 1, 3, and 6 months. Each was read by a single musculoskeletal radiologist and categorized as "intact," "torn," or "unclear." Clinical outcome was evaluated using the Western Ontario Osteoarthritis Shoulder (WOOS) index at these same time points. RESULTS: The final study group consisted of 35 procedures in 33 patients (19 females and 14 males, mean age 66 ± 9 years). Three patients had postoperative subscapularis failures that were confirmed in the operating room at the time of repair. Of 24 sonographs categorized as "unclear" in the postoperative period, the majority (n = 12, 50%) were taken at 1 week. Compared to preoperative scores, patients had lower WOOS scores at 1, 3, and 6 months postoperatively (P < .001). Correlation analysis did not reveal an association between the ultrasound readings and the WOOS scores postoperatively. CONCLUSION: The utility of ultrasound examination of the subscapularis tendon following shoulder arthroplasty is limited by timing and may be most useful when used by the physician within clinical context. Significant improvement was noted in disease-specific quality-of-life scores regardless of the status of the subscapularis tendon as read on ultrasound.

2.
Hand Clin ; 34(1): 113-120, 2018 02.
Article in English | MEDLINE | ID: mdl-29169592

ABSTRACT

Patients who require assistive devices with their hands for mobilization are called functional quadrupeds. These patients pose a unique challenge after they have a distal radius fracture, as their injury not only limits the wrist but also compromises ambulation. The authors propose a different treatment strategy for functional quadrupeds to improve mobilization and weight-bearing with the injured limb after a distal radius fracture. In this article, the authors define the functional quadruped and describe their technique of spanning bridge plate fixation with a retrospective review of patient outcomes.


Subject(s)
Bone Plates , Disabled Persons , Fracture Fixation, Internal/methods , Radius Fractures/surgery , Aged , Aged, 80 and over , Humans , Middle Aged
3.
Bone ; 84: 93-103, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26723577

ABSTRACT

Recombinant human BMP-2 (rhBMP-2) is a potent osteoinductive agent, but has been associated not only with bone formation, but also osteoclastogenesis and bone resorption. Osteoprotegerin (OPG) is a RANKL inhibitor that blocks differentiation and function of osteoclasts. We hypothesized that the combination of local BMP-2 (recombinant protein or a product of gene therapy) plus systemic OPG-Fc is more effective than BMP-2 alone in promoting bone repair. To test this hypothesis we used a mouse critical-sized femoral defect model. Col2.3eGFP (osteoblastic marker) male mice were treated with rhBMP-2 (group I), rhBMP-2 and systemic OPG (group II), rhBMP-2 and delayed administration of OPG (group III), mouse BM cells transduced with a lentiviral vector containing the BMP-2 gene (LV-BMP-2; group IV), LV-BMP-2 and systemic OPG (group V), a carrier alone (group VI) and administration of OPG alone (group VII). All bone defects treated with BMP-2 (alone or combined with OPG) healed, whereas minimal bone formation was noted in animals treated with the carrier alone or OPG alone. MicroCT analysis showed that bone volume (BV) in rhBMP-2+OPG and LV-BMP-2+OPG groups was significantly higher compared to rhBMP-2 alone (p<0.01) and LV-BMP-2 alone (p<0.001). Similar results were observed in histomorphometry, with rhBMP-2 alone defects exhibiting significantly lower bone area (B.Ar) compared to rhBMP-2+OPG defects (p<0.005) and LV-BMP-2 defects having a significantly lower B.Ar compared to all BMP-2+OPG treated groups (p≤0.01). TRAP staining demonstrated a major osteoclast response in the groups that did not receive OPG (rhBMP-2, LV-BMP-2 and sponge alone) beginning as early as 7days post-operatively. In conclusion, we demonstrated that locally delivered BMP-2 (recombinant protein or gene therapy) in combination with systemically administered OPG improved bone healing compared to BMP-2 alone in a mouse critical-sized bone defect. These data indicate that osteoclasts can diminish healing responses to BMP-2 and that RANKL inhibition may thus accentuate BMP-2 efficacy.


Subject(s)
Bone Morphogenetic Protein 2/pharmacology , Femur/pathology , Osteoprotegerin/pharmacology , RANK Ligand/antagonists & inhibitors , Transforming Growth Factor beta/pharmacology , Wound Healing/drug effects , Acid Phosphatase/metabolism , Animals , Cell Count , Drug Therapy, Combination , Femur/diagnostic imaging , Femur/drug effects , Femur/surgery , Frozen Sections , Humans , Isoenzymes/metabolism , Lentivirus/genetics , Male , Mice, Inbred C57BL , Osteoclasts/drug effects , Osteoclasts/pathology , Osteogenesis , RANK Ligand/metabolism , Recombinant Proteins/pharmacology , Tartrate-Resistant Acid Phosphatase , Transduction, Genetic , X-Ray Microtomography
4.
J Bone Joint Surg Am ; 97(22): 1852-9, 2015 Nov 18.
Article in English | MEDLINE | ID: mdl-26582615

ABSTRACT

BACKGROUND: Recombinant human bone morphogenetic protein (rhBMP)-2 is a potent osteoinductive agent; however, its clinical use has been reduced because of safety and efficacy concerns. In preclinical studies involving a critical-sized defect in a rat model, sclerostin antibody (Scl-Ab) treatment increased bone formation within the defect but did not result in reliable healing. The purpose of the current study was to evaluate bone repair of a critical-sized femoral defect in a rat model with use of local implantation of rhBMP-2 combined with systemic administration of Scl-Ab. METHODS: A critical-sized femoral defect was created in rats randomized into three treatment groups: local rhBMP-2 and systemic Scl-Ab (Scl + BMP), local rhBMP-2 alone, and collagen sponge alone (operative control). The Scl + BMP group received local rhBMP-2 (10 µg) on a collagen sponge placed within the defect intraoperatively and then twice weekly injections of Scl-Ab (25 mg/kg) administered postoperatively. The femora were evaluated at twelve weeks with use of radiography, microcomputed tomography (microCT), histomorphometric analysis, and biomechanical testing. RESULTS: At twelve weeks, all Scl + BMP and rhBMP-2 only samples were healed. No femora healed in the operative control group. Histomorphometric analysis demonstrated more bone in the Scl + BMP samples than in the samples treated with rhBMP-2 alone (p = 0.029) and the control samples (p = 0.003). MicroCT revealed that the Scl + BMP group had a 90% greater bone volume within the defect region compared with the rhBMP-2 group and a 350% greater bone volume compared with the operative control group (p < 0.001). Biomechanical testing showed that the group treated with Scl + BMP had greater torsional strength and rigidity compared with the rhBMP-2 group (p < 0.001 and p = 0.047) and the intact femoral control group (p < 0.001). Torque to failure was lower in the rhBMP-2 group compared with the intact femoral control group (p < 0.002). Mean energy to failure was higher in the Scl + BMP samples compared with the rhBMP-2 only samples (p = 0.001). CONCLUSIONS: In a critical-sized femoral defect in a rat model, local rhBMP-2 combined with systemic administration of Scl-Ab resulted in more robust healing that was stronger and more rigid than results for rhBMP-2 alone and intact nonoperative femora. CLINICAL RELEVANCE: Our study demonstrated that combining an osteoinductive agent with a systemically administered antibody that promotes bone formation can enhance bone repair and has potential as a therapeutic regimen in humans.


Subject(s)
Bone Density Conservation Agents/therapeutic use , Bone Morphogenetic Protein 2/therapeutic use , Bone Morphogenetic Proteins/therapeutic use , Femoral Fractures/drug therapy , Fracture Fixation, Internal , Transforming Growth Factor beta/therapeutic use , Adaptor Proteins, Signal Transducing , Animals , Chemotherapy, Adjuvant , Drug Administration Schedule , Drug Therapy, Combination , Femoral Fractures/diagnostic imaging , Femoral Fractures/pathology , Femoral Fractures/surgery , Fracture Healing , Genetic Markers , Humans , Injections, Subcutaneous , Male , Radiography , Random Allocation , Rats , Recombinant Proteins/therapeutic use
5.
J Am Acad Orthop Surg ; 21(5): 268-75, 2013 May.
Article in English | MEDLINE | ID: mdl-23637145

ABSTRACT

Dysfunction of the median nerve at the elbow or proximal forearm can characterize two distinct clinical entities: pronator syndrome (PS) or anterior interosseous nerve (AIN) syndrome. PS is characterized by vague volar forearm pain, with median nerve paresthesias and minimal motor findings. AIN syndrome is a pure motor palsy of any or all of the muscles innervated by that nerve: the flexor pollicis longus, the flexor digitorum profundus of the index and middle fingers, and the pronator quadratus. The sites of anatomic compression are essentially the same for both disorders. Typically, the findings of electrodiagnostic studies are normal in patients with PS and abnormal in those with AIN syndrome. PS is a controversial diagnosis and is typically treated nonsurgically. AIN syndrome is increasingly thought to be neuritis and it often resolves spontaneously following prolonged observation. Surgical indications for nerve decompression include persistent symptoms for >6 months in patients with PS or for a minimum of 12 months with no signs of motor improvement in those with AIN syndrome.


Subject(s)
Median Neuropathy/diagnosis , Decompression, Surgical , Diagnosis, Differential , Forearm/innervation , Humans , Median Nerve/anatomy & histology , Median Neuropathy/surgery , Median Neuropathy/therapy , Nerve Compression Syndromes/diagnosis , Nerve Compression Syndromes/surgery , Physical Examination , Syndrome
SELECTION OF CITATIONS
SEARCH DETAIL
...